OncoMatch/Clinical Trials/NCT06567743
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Is NCT06567743 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cretostimogene Grenadenorepvec for high-risk non-muscle-invasive bladder cancer.
Treatment: Cretostimogene Grenadenorepvec — This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage CIS
Excluded: Stage MUSCLE-INVASIVE, III, IV
Grade: high-grade
CIS with or without Ta/T1 disease or high-grade Ta/T1 papillary-only disease without CIS
Prior therapy
Must have received: BCG — naïve
BCG-naïve high-risk high-grade NMIBC
Cannot have received: gemcitabine
Cohort CX Only: serial intravesical gemcitabine within 24 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Phoenix, Arizona
- Arizona Urology Specialty · Tucson, Arizona
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- Arkansas Urology · Little Rock, Arkansas
- Michael G Oefelein, MD Clinical Trials · Bakersfield, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify